All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
The Lymphoma Hub is happy to present a Visual Abstract representing key data from the primary analysis of the phase III ZUMA-7 study (NCT03391466), evaluating the clinical efficacy of axicabtagene ciloleucel versus standard-of-care second-line therapy in adult patients with relapsed/refractory large B-cell lymphoma.
To download this visual abstract, click below!
Download hereVisual Abstract
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Visual Abstract | A real-world comparison of treatment with tisagenlecleucel and axicabtagene ciloleucel in patients with R/R DLBCL
The Lymphoma Hub is pleased to present a visual abstract summarizing key points from the recent real-world comparison...
Visual abstract | Final analysis of the phase III iLLUMINATE trial in patients with CLL/SLL
A visual summary of key data from the phase III iLLUMINATE trial evaluating the clinical efficacy of ibrutinib plus obinutuzumab vs chlorambucil plus...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox